Ibio Inc (NYSEMKT:IBIO) saw a huge move towards the end of 2014 from $0.50 to $3.50 on speculation that IBIO might just be THE manufacture partner in the government’s efforts to ramp up production of Mapp Biopharmaceuticals’ Ebola drug ZMapp. Since then IBIO has dropped significantly hitting lows of $0.40 a share before a recent recovery and move up.
Back in October of last year IBIO offered to assist the U.S. government by making its proprietary antibody production technology available to deal with the current Ebola virus outbreak. In response to shareholder and media inquiries, the company said the way it produces, in collaboration with Caliber Biotherapeutics, pharmaceutical proteins in plants has proven to have efficacy advantages over similar antibodies produced in Chinese hamster ovary cells. The stock has roughly quadrupled year to date through Wednesday, as the Ebola virus outbreak spread. On Thursday, an Air France aircraft flying from Paris was grounded in Madrid amid concerns one of the passengers onboard had Ebola.
Ibio Inc (NYSEMKT:IBIO) is developing a proprietary product, IBIO-CFB03, for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases using its iBioLaunch(TM) platform. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch and iBioModulator(TM) platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
To Find out the inside Scoop on IBIO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect.
On October 16 IBIO confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.
Based on published scientific data, the superior homogeneity of antibody glysolylation (the addition of sugars to proteins) in plants can provide significant efficacy advantages over similar antibodies produced in Chinese hamster ovary (CHO) cells.
Conclusion: IBIO is dropping south of $1 on accelerating volume.
We Have a MASSIVE Stock Pick Coming ASAP. Only a Crazy Person would Miss this!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Confirmed reports coming from a number of investors in the know suggest that IBIO is NOT in fact the manufacture partner to the government. In any case this stock is currently receiving massive publicity and could easily continue on way higher from here.
Currently trading at a $200 million market valuation IBIO is one of the top traded stocks on the entire small cap market right now and might provide another spectacular trade opportunity this week.
Disclosure: we hold no position in IBIO either long or short and we have not been compensated for this article.